<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000446802"><TermName>galiximab</TermName><TermPronunciation>(guh-LIK-sih-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of follicular non-Hodgkin lymphoma. It binds to the protein CD80, which is found on certain normal white blood cells and on white blood cells that are cancer. It is a type of monoclonal antibody.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000714759" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;galiximab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000714758" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;galiximab&quot;" language="es" id="_4"/><SpanishTermName>galiximab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de linfoma folicular no Hodgkin. Esta se une a la proteína CD80, que se encuentra en ciertos glóbulos blancos normales y en glóbulos blancos que son cancerosos. Es un tipo de anticuerpo monoclonal.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-12-22</DateFirstPublished><DateLastModified>2009-06-26</DateLastModified></GlossaryTerm>
